Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Lose 14-15% of your body weight* *In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise
Currently, Wegovy targets one hormone (GLP-1), and Zepbound targets two (GLP-1 and GIP)
Their effects on energy levels are indirect, mediated through improvements in metabolic parameters, weight reduction, and glycemic stability
Hypoglycaemia (low blood sugar) can manifest as fatigue, dizziness, and weakness
Novo Nordisk and Eli Lilly, makers of the other popular GLP-1 drug, tirzepatide, have also sued specific pharmacies and distributors
